Capital Research Global Investors Has $82.96 Million Stake in Masimo Corporation $MASI

Capital Research Global Investors trimmed its holdings in Masimo Corporation (NASDAQ:MASI) by 65.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 637,894 shares of the medical equipment provider’s stock after selling 1,216,234 shares during the period. Capital Research Global Investors owned 1.19% of Masimo worth $82,964,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in MASI. Royal Bank of Canada lifted its position in shares of Masimo by 44.5% in the first quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock valued at $7,311,000 after buying an additional 13,513 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Masimo by 136.5% in the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after buying an additional 4,700 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after buying an additional 66 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Masimo in the first quarter valued at approximately $220,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after buying an additional 2,040 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MASI shares. Weiss Ratings raised Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective for the company. in a research report on Tuesday, February 17th. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Wells Fargo & Company raised Masimo to a “hold” rating in a report on Wednesday, March 18th. Finally, Wolfe Research cut Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Nine research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $180.40.

Masimo Stock Performance

NASDAQ:MASI opened at $179.94 on Tuesday. The stock has a market cap of $9.42 billion, a P/E ratio of -17.07, a PEG ratio of 1.81 and a beta of 1.11. The stock has a 50 day simple moving average of $178.51 and a 200 day simple moving average of $159.66. The company has a current ratio of 2.68, a quick ratio of 1.45 and a debt-to-equity ratio of 0.56. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $179.97.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.